Development of Human Natural Killer Cells and Other Innate Lymphoid Cells
Overview
Affiliations
Innate lymphoid cells (ILC) have recently gained much attention in immunology. They represent a novel developmentally related family. Three distinct subsets have been identified on the basis of phenotypic and functional criteria and termed ILC1, ILC2, and ILC3. The available data suggest that ILC play an important role in innate defenses against different pathogens, in lymphoid organogenesis, and in tissue remodeling. All these aspects are relevant in hematopoietic stem cell transplantation (HSCT), particularly in the haplo-HSCT setting, in which donor NK cells are known to play a major therapeutic role, while the involvement of other ILC is still undefined. In this context, it has been postulated that all ILC share a common precursor expressing the ID2 transcription factor. While the differentiation of human NK cells (belonging to ILC1) is now well characterized both in vitro and in vivo, limited information is available on the development of human ILC2 and ILC3 and of their relationships with NK cells. In this review, we will summarize the present knowledge on the developmental relationship among different ILC, with particular focus on early stages of NK cell differentiation, and their features shared with ILC2 and ILC3.
Martin Corredera M, Paillet J, Gaudeaux P, Blein T, Sadek H, Rault P Front Immunol. 2025; 16:1531736.
PMID: 40051631 PMC: 11883473. DOI: 10.3389/fimmu.2025.1531736.
Prognostic biomarker HIF1α and its correlation with immune infiltration in gliomas.
Ding Z, Zhang J, Li L, Wang C, Mei J Oncol Lett. 2024; 27(5):193.
PMID: 38495835 PMC: 10941081. DOI: 10.3892/ol.2024.14326.
Systemic immune response in young and elderly patients after traumatic brain injury.
Magatti M, Pischiutta F, Ortolano F, Pasotti A, Caruso E, Cargnoni A Immun Ageing. 2023; 20(1):41.
PMID: 37573338 PMC: 10422735. DOI: 10.1186/s12979-023-00369-1.
Low Level FLT3LG is a Novel Poor Prognostic Biomarker for Cervical Cancer with Immune Infiltration.
Chen L, Huang Y, Dong B, Gu Y, Li Y, Cang W J Inflamm Res. 2022; 15:5889-5904.
PMID: 36274829 PMC: 9579815. DOI: 10.2147/JIR.S384908.
Damele L, Spaggiari G, Parodi M, Mingari M, Vitale M, Vitale C Cancers (Basel). 2022; 14(18).
PMID: 36139598 PMC: 9496735. DOI: 10.3390/cancers14184439.